{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:33:49Z","timestamp":1763642029980},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.canlet.2016.01.015","type":"journal-article","created":{"date-parts":[[2016,1,19]],"date-time":"2016-01-19T19:58:33Z","timestamp":1453233513000},"page":"193-202","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Intracellular autocrine VEGF signaling promotes EBDC cell proliferation, which can be inhibited by Apatinib"],"prefix":"10.1016","volume":"373","author":[{"given":"Sui","family":"Peng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zunfu","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianhong","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Tsung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samer","family":"Tohme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Lencioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhirong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baogang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2016.01.015_bib0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11894-008-0008-9","article-title":"Diagnosis and management of cholangiocarcinoma","volume":"10","author":"Sandhu","year":"2008","journal-title":"Curr. Gastroenterol. Rep"},{"key":"10.1016\/j.canlet.2016.01.015_bib0015","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/jnci\/djj234","article-title":"Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States","volume":"98","author":"Welzel","year":"2006","journal-title":"J. Natl Cancer Inst"},{"key":"10.1016\/j.canlet.2016.01.015_bib0020","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1053\/j.gastro.2013.10.011","article-title":"Autocrine VEGF signaling promotes proliferation of neoplastic Barrett's epithelial cells through a PLC-dependent pathway","volume":"146","author":"Zhang","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2016.01.015_bib0025","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0022-5347(05)00736-6","article-title":"Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer","volume":"175","author":"Xia","year":"2006","journal-title":"J. Urol"},{"key":"10.1016\/j.canlet.2016.01.015_bib0030","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1172\/JCI65385","article-title":"Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer","volume":"123","author":"Chatterjee","year":"2013","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.canlet.2016.01.015_bib0035","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1200\/JCO.2007.15.9947","article-title":"Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma","volume":"26","author":"Siegel","year":"2008","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.canlet.2016.01.015_bib0040","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","article-title":"Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial","volume":"31","author":"Cheng","year":"2013","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.canlet.2016.01.015_bib0045","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/hep.22310","article-title":"Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment","volume":"48","author":"Blechacz","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2016.01.015_bib0050","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.canlet.2016.01.015_bib0055","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/sj.bjc.6605458","article-title":"Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial","volume":"102","author":"Bengala","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2016.01.015_bib0060","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/sj.bjc.6604129","article-title":"Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma","volume":"98","author":"Yoshikawa","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2016.01.015_bib0065","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4143\/crt.2013.45.1.63","article-title":"ERCC1 can be a prognostic factor in hilar cholangiocarcinoma and extrahepatic bile duct cancer, but not in intrahepatic cholangiocarcinoma","volume":"45","author":"Park","year":"2013","journal-title":"Cancer Res. Treat"},{"key":"10.1016\/j.canlet.2016.01.015_bib0070","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1756-9966-28-62","article-title":"Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract","volume":"28","author":"Miller","year":"2009","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2016.01.015_bib0075","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/cncr.20906","article-title":"Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma","volume":"103","author":"Wakai","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2016.01.015_bib0080","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1349-7006.2011.01939.x","article-title":"YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo","volume":"102","author":"Tian","year":"2011","journal-title":"Cancer Sci"},{"key":"10.1016\/j.canlet.2016.01.015_bib0085","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2013.48.8585","article-title":"Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial","volume":"31","author":"Li","year":"2013","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.canlet.2016.01.015_bib0090","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1186\/1471-2407-14-820","article-title":"Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer","volume":"14","author":"Hu","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2016.01.015_bib0095","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ctrv.2012.05.003","article-title":"Targeted agents in the third-\/fourth-line treatment of patients with advanced (stage III\/IV) non-small cell lung cancer (NSCLC)","volume":"39","author":"Langer","year":"2013","journal-title":"Cancer Treat. Rev"},{"key":"10.1016\/j.canlet.2016.01.015_bib0100","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/hep.27236","article-title":"Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma","volume":"60","author":"Peng","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2016.01.015_bib0105","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1016\/S0960-894X(03)00626-7","article-title":"Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching","volume":"13","author":"Furet","year":"2003","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.canlet.2016.01.015_bib0110","doi-asserted-by":"crossref","first-page":"a006502","DOI":"10.1101\/cshperspect.a006502","article-title":"Signal transduction by vascular endothelial growth factor receptors","volume":"2","author":"Koch","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"10.1016\/j.canlet.2016.01.015_bib0115","doi-asserted-by":"crossref","first-page":"a006593","DOI":"10.1101\/cshperspect.a006593","article-title":"The VEGF pathway in cancer and disease: responses, resistance, and the path forward","volume":"2","author":"Kieran","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"10.1016\/j.canlet.2016.01.015_bib0120","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2016.01.015_bib0125","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S1470-2045(12)70509-0","article-title":"Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial","volume":"13","author":"de Gramont","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canlet.2016.01.015_bib0130","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","article-title":"Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study","volume":"15","author":"Seto","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canlet.2016.01.015_bib0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122555","article-title":"Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymoma","volume":"10","author":"Sie","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.canlet.2016.01.015_bib0140","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1245\/ASO.2006.05.049","article-title":"Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts","volume":"13","author":"Holloway","year":"2006","journal-title":"Ann. Surg. Oncol"},{"issue":"3","key":"10.1016\/j.canlet.2016.01.015_bib0145","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/hep.26384","article-title":"Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma","volume":"58","author":"Cadamuro","year":"2013","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.canlet.2016.01.015_bib0150","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s13277-014-2691-5","article-title":"Secreted cyclophilin A mediates G1\/S phase transition of cholangiocarcinoma cells via CD147\/ERK1\/2 pathway","volume":"36","author":"Obchoei","year":"2015","journal-title":"Tumour Biol"},{"key":"10.1016\/j.canlet.2016.01.015_bib0155","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1083\/jcb.200602080","article-title":"Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments","volume":"174","author":"Lampugnani","year":"2006","journal-title":"J. Cell Biol"},{"key":"10.1016\/j.canlet.2016.01.015_bib0160","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nrc3627","article-title":"VEGF targets the tumour cell","volume":"13","author":"Goel","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2016.01.015_bib0165","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1200\/JCO.2012.46.2762","article-title":"Markers of response for the antiangiogenic agent bevacizumab","volume":"31","author":"Lambrechts","year":"2013","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.canlet.2016.01.015_bib0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4174\/astr.2015.89.1.1","article-title":"Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis","volume":"89","author":"Lee","year":"2015","journal-title":"Ann. Surg. Treat. Res"},{"key":"10.1016\/j.canlet.2016.01.015_bib0175","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1182\/blood-2003-05-1634","article-title":"Internal and external autocrine VEGF\/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways","volume":"103","author":"Santos","year":"2004","journal-title":"Blood"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383516000276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383516000276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T03:52:01Z","timestamp":1537069921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383516000276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0304383516000276"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2016.01.015","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intracellular autocrine VEGF signaling promotes EBDC cell proliferation, which can be inhibited by Apatinib","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2016.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}